Cholestatic jaundice associated with chlorozotocin

Area of Science:

• Oncology
• Hepatology
• Pharmacology

Background:

• Drug-induced liver injury is a significant concern in cancer patients.
• Jaundice in cancer patients can have multiple etiologies, complicating diagnosis.
• Chlorozotocin is a novel antineoplastic agent with a potential for unique toxicities.

Purpose of the Study:

• To present clinical and pathologic findings in three cases of drug-induced cholestatic jaundice.
• To highlight the association between chlorozotocin and hepatotoxicity.
• To emphasize the importance of recognizing this specific adverse drug reaction.

Main Methods:

• Case series presentation.
• Clinical data review.
• Pathologic examination of liver tissue.

Main Results:

• Three patients developed cholestatic jaundice following intermittent high-dose chlorozotocin treatment.
• Histopathologic findings consistent with drug-induced liver injury were observed.
• The jaundice was attributed to chlorozotocin-induced hepatotoxicity.

Conclusions:

• Chlorozotocin can induce a specific form of cholestatic jaundice.
• Early recognition of chlorozotocin-induced hepatotoxicity is vital for patient management.
• This adverse effect warrants consideration in the differential diagnosis of jaundice in patients receiving chlorozotocin.